WVVI vs NBY vs STZ vs SAM vs MGPI

For growth investors, The Boston Beer Company, Inc.

(SAM) is the stronger pick with 3. 7% revenue growth year-over-year, versus -100. 0% for Willamette Valley Vineyards, Inc. (WVVI). The Boston Beer Company, Inc. (SAM) offers the better valuation at 20. 5x trailing P/E (20. 6x forward), making it the more compelling value choice. Analysts rate Constellation Brands, Inc. (STZ) a "Buy" — based on 46 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, MGP Ingredients, Inc.

is actually cheaper at 12. 1x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Constellation Brands, Inc.

(STZ) delivered a total return of -30. 1%, compared to -99. 9% for NovaBay Pharmaceuticals, Inc. (NBY). Over 10 years, the gap is even starker: SAM returned +32. 0% versus NBY's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Willamette Valley Vineyards, Inc.

(WVVI) is the lower-risk stock at -0. 25β versus NovaBay Pharmaceuticals, Inc. 's 2. 43β — meaning NBY is approximately -1067% more volatile than WVVI relative to the S&P 500. On balance sheet safety, The Boston Beer Company, Inc. (SAM) carries a lower debt/equity ratio of 4% versus 170% for Constellation Brands, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), The Boston Beer Company, Inc.

(SAM) is pulling ahead at 3. 7% versus -100. 0% for Willamette Valley Vineyards, Inc. (WVVI). On earnings-per-share growth, the picture is similar: NovaBay Pharmaceuticals, Inc. grew EPS 98. 2% year-over-year, compared to -419. 9% for MGP Ingredients, Inc.. Over a 3-year CAGR, STZ leads at 5. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

The Boston Beer Company, Inc.

(SAM) is the more profitable company, earning 5. 2% net margin versus -73. 8% for NovaBay Pharmaceuticals, Inc. — meaning it keeps 5. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: STZ leads at 35. 5% versus -59. 7% for NBY. At the gross margin level — before operating expenses — NBY leads at 66. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, MGP Ingredients, Inc.

(MGPI) trades at 12. 1x forward P/E versus 20. 6x for The Boston Beer Company, Inc. — 8. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MGPI: 51. 9% to $29. 00.

In this comparison, WVVI (100.

0% yield), STZ (2. 7% yield), MGPI (2. 5% yield) pay a dividend. NBY, SAM do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Willamette Valley Vineyards, Inc.

(WVVI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 25), 100. 0% yield). NovaBay Pharmaceuticals, Inc. (NBY) carries a higher beta of 2. 43 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (WVVI: -59. 3%, NBY: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (WVVI (Consumer Defensive) and NBY (Healthcare) and STZ (Consumer Defensive) and SAM (Consumer Defensive) and MGPI (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: WVVI is a small-cap income-oriented stock; NBY is a small-cap quality compounder stock; STZ is a mid-cap quality compounder stock; SAM is a small-cap quality compounder stock; MGPI is a small-cap quality compounder stock. WVVI, STZ, MGPI pay a dividend while NBY, SAM do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.